logo
Plus   Neg
Share
Email

Teva Launches Truxima Injection In U.S. To Treat Rheumatoid Arthritis

Teva Pharmaceutical Industries Ltd. (TEVA) and Celltrion Healthcare have launched Truxima Injection in the United States for the treatment of Rheumatoid Arthritis.

Truxima is also now available for the treatment of Granulomatosis with Polyangiitis and Microscopic Polyangiitis.

TRUXIMA is the only biosimilar to the reference product Rituxan available to treat rheumatoid arthritis in the United States.

Celltrion Healthcare and Teva entered into an exclusive partnership in October 2016 for Teva to commercialize TRUXIMA in the U.S. and Canada.

TRUXIMA is expected to be available through primary wholesalers at a list price of $845.55 per 100mg vial and $4,227.75 per 500mg vial.

Teva also offers dedicated patient support services through the CORE program. CORE is available to help eligible patients, caregivers and healthcare professionals navigate the reimbursement process.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Moderna said Tuesday that it has reached an agreement with the U.S. to initially supply 100 million doses of its experimental vaccine for COVID-19, mRNA-1273. The U.S. government has awarded up to $1.525 billion for the vaccine. Las Vegas, Nevada-based Mr. Wok Foods has recalled about 200,000 pounds of meat and poultry products for misbranding and undeclared allergens, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The recalled products may contain known allergens such as milk, wheat, soy, peanuts, or oysters. They may also contain MSG, sesame products, or sulfites. The U.S. Food and Drug Administration approved the first oral drug to treat patients two months of age and older with spinal muscular atrophy (SMA) that can be taken at home. Roche subsidiary Genentech's Evrysdi (risdiplam) is also the second FDA-approved drug to treat this rare and often fatal genetic disease affecting muscle strength and movement.
Follow RTT